Related Experiment Video
Updated: Jul 29, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
Extended-release tofacitinib for refractory Behçet disease: A case report
Chrong-Reen Wang1, Tak-Wah Wong2, Sheng-Min Hsu3
1Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Medicine
|April 27, 2022
Summary
Extended-release tofacitinib (TOF) offers a convenient and effective treatment for severe Behçet disease (BD). This oral medication achieved disease remission in a refractory BD patient, reducing the need for corticosteroids.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Behçet disease (BD) involves complex multi-cytokine pathways, often necessitating targeted therapies.
- Tofacitinib (TOF), a Janus kinase inhibitor, is increasingly used for systemic vasculitis, but extended-release formulations lack reported efficacy data in BD.
- Conventional treatments for severe BD carry risks, including opportunistic infections.
Observation:
- A 27-year-old woman with a 3-year history of refractory Behçet disease presented with arthritis, orogenital ulcers, skin lesions, and uveitis.
- The patient had previously undergone long-term corticosteroid and immunosuppressant therapy, complicated by candidiasis.
Findings:
- Once-daily administration of extended-release tofacitinib (11 mg) led to complete disease remission.
- Corticosteroid use was successfully discontinued during the follow-up period.
Implications:
- Extended-release tofacitinib demonstrates significant therapeutic efficacy in managing Behçet disease activity.
- The oral convenience of this formulation may improve patient adherence and treatment outcomes in refractory BD.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...